TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
Jin Won Kim(Seoul National University), Yung‐Jue Bang(Seoul National University Hospital)
Cited by 8
Related Papers
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
|Breast Cancer Research|2015|176
Therapeutic implication of HER2 in advanced biliary tract cancer
|Oncotarget|2016|86
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
|Cancer Research and Treatment|2018|31
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
|Cancer Research and Treatment|2020|21